Slavica BioChem (HTDS) Releases Its Bio Chem Expenditures 2009

BELGRADE, SERBIA, March 23 /PRNewswire-FirstCall/ - Slavica Biochem (http://www.slavicabiochem.com), registered subsidiary of Hard to Treat Diseases (http://www.htdsmedical.com), has released its RD (research and development) expenditures for 2009.

The List comprises of expenses connected with the purchase of laboratory equipment, travel and other miscellaneous expenses necessary for the operation, cooperation and coordination of Slavica BioChem's business and research. As HTDS does not subscribe to Pink Sheets filing service. The company followers may review this exhausting list of expenditures on the company IR web site 'Filings and News' section. See "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/

Slavica BioChem also continues its commitment to a development of its own division devoted to Regenerative medicine.

Regenerative Medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. This field holds the promise of regenerating damaged tissues and organs in the body by stimulating previously irreparable organs to heal themselves.

Scientific research is working to make treatments available for clinical use. Treatments include both in vivo and in vitro procedures. In vivo meaning studies and trials performed inside the living body in order to stimulate previously irreparable organs to heal themselves. In vitro treatments are applied to the body through implantation of a therapy studied inside the laboratory.

The company will advise the shareholders on all developments in timely manner.

The company reminds its shareholders and followers to our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases